文献速递炎症性肠病

生物制剂初治溃疡性结肠炎患者英夫利西单抗优先与维得利珠单抗优先治疗策略的长期结局

Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2024-12-11

该回顾性队列研究纳入181例生物制剂初治溃疡性结肠炎患者(维得利珠单抗优先94例,英夫利西单抗优先87例),其中144例经1:1匹配,随访30个月。两组在IBD相关住院、糖皮质激素疗程、严重感染及换药比例上均无显著差异,30个月临床缓解和內镜缓解比例亦无差异。

要点

  • 生物制剂初治UC患者中,英夫利西单抗优先与维得利珠单抗优先策略30个月疗效与安全性相当。
  • 两组IBD相关住院、激素疗程、严重感染及换药率均无显著差异。
  • 30个月临床缓解69.4% vs 76.4%(p=0.45),内镜缓解55.6% vs 65.3%(p=0.36)。

核心结论

  • 在溃疡性结肠炎患者中,英夫利西单抗优先与维得利珠单抗优先治疗策略在30个月时的长期有效性和安全性结局相当,可帮助指导UC患者治疗策略的选择。

研究设计与样本

  • 回顾性队列研究,纳入2015年至2021年间首次接受英夫利西单抗或维得利珠单抗治疗的生物制剂初治溃疡性结肠炎患者,随访至开始治疗后30个月。
  • 共纳入181例患者(维得利珠单抗优先94例,英夫利西单抗优先87例),其中144例经基数匹配1:1配对,采用logistic回归和零膨胀负二项模型比较结局。

主要发现

  • IBD相关住院发生率无显著差异(发生率比[IRR] 1.98,95%CI 0.64-6.10)。
  • 糖皮质激素疗程无显著差异(IRR 0.66,95%CI 0.38-1.15)。
  • 严重感染无显著差异(IRR 5.26,95%CI 0.62-45.45)。
  • 换用其他先进治疗的比例相当(IRR 1.08,95%CI 0.42-2.81)。
  • 30个月时临床缓解比例无差异(69.4% vs 76.4%,p=0.45),内镜缓解比例无差异(55.6% vs 65.3%,p=0.36)。

关键数值与推荐

  • 主要结局为30个月内住院次数、糖皮质激素疗程数和严重感染数(无论是否换用替代治疗)。
  • 采用基数匹配1:1配对,logistic回归和零膨胀负二项模型比较结局。

临床怎么用

  • 原文结论指出,英夫利西单抗优先与维得利珠单抗优先策略的长期有效性和安全性相当,可帮助指导UC患者治疗策略的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although studies have compared on-treatment effectiveness of infliximab and vedolizumab in patients with ulcerative colitis (UC), there has been limited comparison of treatment sequencing and long-term patient-centred outcomes. AIM: To compare infliximab-first and vedolizumab-first strategy in biologic-naïve patients with UC. METHODS: We conducted a retrospective cohort study in biologic-naïve patients with UC who were treated first with either infliximab or vedolizumab between 2015 and 2021 and followed over 30 months following initiation. Primary outcomes were the number of hospitalisations, corticosteroid courses and serious infections with either strategy (regardless of switch to alternative therapies) within 30 months. We matched the groups 1:1 through cardinality matching, and fit logistic and zero-inflated negative binomial models to compare outcomes. RESULTS: We included 181 patients (94 vedolizumab-first and 87 infliximab-first treatment strategy). Of these, 144 were matched 1:1. There was no significant difference in the incidence of IBD-related hospitalisations (incidence rate ratio [IRR], 1.98 [95% CI, 0.64-6.10]), corticosteroid courses (0.66 [0.38-1.15]) and serious infections (5.26 [0.62-45.45]), with comparable incidence of medication switches to alternative advanced therapies (1.08 [0.42-2.81]). At 30 months, there was no difference in proportion of patients in clinical remission (69.4% vs. 76.4%; p = 0.45) and endoscopic remission (55.6% vs. 65.3%; p = 0.36). CONCLUSION: In patients with UC, long-term effectiveness and safety outcomes are comparable with infliximab-first and vedolizumab-first treatment strategies at 30 months. This can help to guide selection of treatment strategies in patients with UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Haynesworth A, Yeh KH, Lee HH, et al. Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis. Aliment Pharmacol Ther. 2024. PMID: 39660680. doi:10.1111/apt.18441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。